1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3.
Level 5 - mechanism / opinion, no new human data
In vitro bench research using human T cells (mechanism-based reasoning)
PubMed 19843932 · doi:10.4049/jimmunol.0803217
What was done
Investigators stimulated human CD4(+)CD25(-) T cells in vitro with the active form of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), and assessed its impact with and without IL-2 on T cell proliferation, proinflammatory cytokine production (IFN-gamma, IL-17, IL-21), expression of regulatory markers (CTLA-4, FoxP3), and suppressive capacity against responder T cells.
What was found
Stimulation of CD4(+)CD25(-) T cells with 1,25(OH)(2)D(3) inhibited production of IFN-gamma, IL-17, and IL-21 without substantially affecting T cell division. 1,25(OH)(2)D(3) stimulated expression of high levels of CTLA-4, and stimulated FoxP3 expression in the presence of IL-2. Treated cells functionally suppressed the proliferation of normally responsive T cells. The abstract reports no numerical values, concentrations, or statistical metrics.
Why it matters
This study provides a direct mechanistic explanation for how active vitamin D and IL-2 synergize to suppress inflammatory cytokine output and induce functional adaptive regulatory T cells in human immune cell populations.
Limits
The study is entirely in vitro, which limits direct translation to in vivo or clinical therapeutic contexts. The abstract does not specify the donor sample size (n), concentrations used, or quantitative effect sizes for cytokine reduction and suppressive activity.
Cited by
- supports Vitamin D binding to immune cells shifts them away from a pro-inflammatory state.